Wen Ge Han

Roche Pharmaceuticals provides research and development services in the fields of pharmaceuticals and diagnostics. It also provides diagnostics and drugs for cancer and transplantation. The company is headquartered in Nutley, NJ.

Hoffmann-La Roche, Inc. manufactures pharmaceutical drugs. Its products include influenza fighter Tamiflu, controversial acne medication Accutane, HIV inhibitor Fuzeon, obesity drug Xenical, and hepatitis C therapy Pegasys. The company was founded in 1896 Roche and is headquartered in Nutley, NJ.

Bozhou Chinese Herbal Medicines Trading Center Mgmt Co. Ltd. is a company based in Bozhou, China. The company manages a trading center for Chinese herbal medicines.

Coland Pharmaceutical is a specialty pharmaceutical company focusing on marketing branded products and developing solid pipelines through collaboration with leading institutes. Its main interests are in the dedicated therapeutic areas Hepatitis, Immunology, Oncology, and other niche areas. Coland was started its sales operation in 2005. Daiding (Adefovir), a first-to-market generic that treats HBV was launched in 2005. With effective promotion, and brand building, Daiding achieved great success and gained the leading position in China. Its goal is to become a leading specialty pharmaceutical company in China with strong sales and marketing capabilities and solid product pipelines. The company was founded in 2003 and is headquartered in Shanghai, China.

Tianjin Institute of Pharmaceutical Research Co., Ltd. engages in the in the development of various new products such as innovative drugs, generic drugs, new preparations, traditional Chinese medicines, and biological drugs with particular emphasis on the engineering and industrialization of new technologies to meet drug registration requirements. The company was founded in 1959 and is headquartered in Tianjin, China.

Hua Medicine (Shanghai) Co., Ltd. is a Chinese biotechnology company that focuses on the clinical needs of diabetic patients. The private company is based in Shanghai, China. The company has brought together high-end talents and scientific and technological resources to develop the world's first dorzagliatin (hms5552) for the treatment of type 2 diabetes. Hua Medicine has conducted two phase III clinical trials in 2019, targeting type 2 diabetes patients who have failed to treat the disease with other medications. The company plans to expand the advanced concepts of personalized therapy and management of diabetes to achieve effective control of diabetes and metabolic diseases and complications. The company was founded in 2011 by Li Chen, who has been the CEO since then.